UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1224-8
Program Prior Authorization/Notification
Medication Carbaglu® (carglumic acid)
P&T Approval Date 7/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background
Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in
pediatric and adult patients as maintenance therapy for the treatment of chronic
hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, adjunctive therapy to
standard of care for the treatment of acute hyperammonemia due to NAGS deficiency, and
adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to
propionic acidemia (PA) or methylmalonic acidemia (MMA).
Coverage for Carbaglu will be provided for patients who meet the following criteria:
2. Coverage Criteriaa:
A. Initial Authorization
1. Carbaglu will be approved based on the following criterion:
a. Diagnosis of hyperammonemia due to one of the following:
(1) N-acetylglutamate synthase (NAGS) deficiency
(2) Propionic acidemia (PA)
(3) Methylmalonic acidemia (MMA)
Authorization will be issued for 12 months.
B. Reauthorization
1. Carbaglu will be approved based on the following criterion:
a. Documentation of positive clinical response to Carbaglu therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limitations may be in place.
4. References:
1. Carbaglu® [package insert], Lebanon, NJ: Recordati Rare Diseases Inc..; January 2024.
Program Prior Authorization/Notification – Carbaglu (carglumic acid)
Change Control
7/2017 New program.
7/2018 Annual review with no change to coverage criteria. Updated reference.
7/2019 Annual review with no change to coverage criteria.
7/2020 Annual review with no change to coverage criteria. Updated
background and reference.
7/2021 Annual review. Added criteria for hyperammonemia due to propionic
acidemia (PA) or methylmalonic acidemia (MMA). Updated
background and reference.
7/2022 Annual review with no change to coverage criteria. Added state
mandate disclaimer.
7/2023 Annual review. Updated reference.
7/2024 Annual review with no changes to coverage criteria. Updated reference.
© 2024 UnitedHealthcare Services Inc.
2